India Liver Cancer Therapeutics Market, By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, and Liver Metastasis), By Therapy (Targeted Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, and Others), By Route of Administration (Oral, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region, Competition, Forecast, and Opportunities, 2029
India liver cancer therapeutics market is anticipated to witness impressive growth during the forecast period. This can be ascribed due to the rising occurrence of liver cancer. The incidence of liver cancer in India has been steadily rising over the past few decades, with risk factors such as chronic viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease contributing to the increasing burden of the disease. Advances in medical technology have led to the development of new and more effective treatments for liver cancer, including targeted therapies and immunotherapies, which have significantly improved patient outcomes. Early detection and treatment are critical to improving outcomes for liver cancer patients. As awareness of the disease and the importance of early detection continues to grow, more people are seeking medical attention and receiving timely diagnosis and treatment. The Indian government has been increasing its healthcare spending in recent years, which has led to greater access to medical care and improved patient outcomes. This has contributed to the growth of the liver cancer therapeutics market by enabling more patients to receive timely and effective treatment. Public health initiatives, including awareness campaigns and screening programs, have played a crucial role in increasing awareness about the importance of early diagnosis and treatment for liver cancer. Several healthcare organizations and advocacy groups have also been working to improve access to screening and treatment options for liver cancer patients. There has been shift toward personalized medicine as personalized medicines involve tailoring treatment to an individual's specific genetic and molecular characteristics.
Rising Cases of Cirrhosis
Cirrhosis is a condition where the liver becomes scarred and damaged over time, often due to chronic alcohol abuse, viral hepatitis, or other liver diseases. The damage to the liver cells caused by cirrhosis can lead to the development of liver cancer over time. Cirrhosis can increase the risk of liver cancer in several ways. Firstly, the scar tissue that forms in the liver can disrupt normal liver function and make it more difficult for the liver to remove toxins and other harmful substances from the body. This can increase the risk of DNA damage and mutations that can lead to the development of liver cancer. Secondly, cirrhosis can increase the risk of chronic inflammation in the liver, which can further damage liver cells and increase the risk of liver cancer. This is because chronic inflammation can lead to the formation of scar tissue and the activation of signaling pathways that promote the growth and survival of cancer cells. Thirdly, people with cirrhosis may be more likely to have a history of other risk factors for liver cancer, such as chronic viral hepatitis, alcohol abuse, or exposure to environmental toxins. Thus, cirrhosis is a significant risk factor for the development of liver cancer, and people with cirrhosis should undergo regular medical check-ups and screenings. Such factors will drive the growth of the India liver cancer therapeutics market during the forecast period.
Development in Medical Technology
There have been several advancements in liver cancer therapeutics in recent years. Some of these advancements include targeted therapies. These therapies are drugs that are designed to specifically target cancer cells while sparing healthy cells. There are several targeted therapies approved for the treatment of liver cancer, including sorafenib, regorafenib, and lenvatini. Immunotherapy is a type of treatment that uses the body's own immune system to fight cancer. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have been approved for the treatment of liver cancer. Combination therapies involve using multiple drugs or treatment modalities to treat cancer. Several combination therapies have been approved for the treatment of liver cancer, including the combination of atezolizumab and bevacizumab. Surgical techniques for liver cancer have improved in recent years, including the use of laparoscopic and robotic surgeries. Laparoscopic and robotic surgeries have become increasingly popular in the treatment of liver cancer in India. These minimally invasive surgical techniques offer several benefits over traditional open surgeries, including smaller incisions, less pain and scarring, faster recovery times, and reduced risk of complications. In laparoscopic surgery, the surgeon makes several small incisions in the abdomen and inserts a laparoscope (a thin, flexible tube with a camera and light) and surgical instruments to remove the tumor. In robotic surgery, the surgeon uses a robotic system to control the surgical instruments and perform the surgery.
Personalized medicines involve tailoring treatment to an individual's specific genetic and molecular characteristics. Advances in genomic testing have allowed for the identification of specific genetic mutations in liver cancer, which can help guide treatment decisions. Such factors will accelerate the growth of the India liver cancer therapeutic market during the forecast period.
Increment in Healthcare Expenditure
As liver cancer is a serious health issue and requires specialized medical care, the cost of treatment can be significant. Therefore, an increase in healthcare expenditure can lead to increased access to medical care for patients with liver cancer, which can help to boost the demand for liver cancer therapeutics in India. Moreover, the Government of India has launched various healthcare initiatives and schemes, such as the Ayushman Bharat scheme, which aims to provide affordable and accessible healthcare to all citizens. Such initiatives and schemes can further boost the demand for liver cancer therapeutics in India, leading to market growth. National Cancer Grid is a network of cancer centers, research institutes, and universities that collaborate to provide standardized cancer care in India. The National Cancer Grid aims to improve the quality of cancer care, including liver cancer, by promoting research, training, and sharing best practices. Make in India aims to promote domestic manufacturing of medical devices and pharmaceuticals in India, including liver cancer therapeutics. By promoting local manufacturing, the initiative aims to reduce the cost of cancer treatment and improve access to affordable liver cancer therapeutics for patients. These initiatives aim to increase access to medical care, improve the quality of cancer care, reduce the cost of cancer treatment, and play a vital role in driving the growth of the India liver cancer therapeutics market.
Market Segmentation
The India liver cancer therapeutics market can be segmented by cancer type, therapy, route of administration, distribution channel, and region. By cancer type, the market can be segmented into hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, and liver metastasis. By therapy, the market can be segmented into targeted therapy, chemotherapy and radiation therapy, immunotherapy, and others. By route of administration, the market can be segmented into oral, intravenous, and others. By distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By region, the market can be segmented into North India, South India, East India, and West India.
Market Players
Natco Pharma Ltd., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Pvt. Ltd., Lupin Ltd., Biocon Ltd., and Hetero Labs Ltd. are some of the market players in the India liver cancer therapeutics market.
Report Scope:
In this report, the India liver cancer therapeutics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the India liver cancer therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Rising Cases of Cirrhosis
Cirrhosis is a condition where the liver becomes scarred and damaged over time, often due to chronic alcohol abuse, viral hepatitis, or other liver diseases. The damage to the liver cells caused by cirrhosis can lead to the development of liver cancer over time. Cirrhosis can increase the risk of liver cancer in several ways. Firstly, the scar tissue that forms in the liver can disrupt normal liver function and make it more difficult for the liver to remove toxins and other harmful substances from the body. This can increase the risk of DNA damage and mutations that can lead to the development of liver cancer. Secondly, cirrhosis can increase the risk of chronic inflammation in the liver, which can further damage liver cells and increase the risk of liver cancer. This is because chronic inflammation can lead to the formation of scar tissue and the activation of signaling pathways that promote the growth and survival of cancer cells. Thirdly, people with cirrhosis may be more likely to have a history of other risk factors for liver cancer, such as chronic viral hepatitis, alcohol abuse, or exposure to environmental toxins. Thus, cirrhosis is a significant risk factor for the development of liver cancer, and people with cirrhosis should undergo regular medical check-ups and screenings. Such factors will drive the growth of the India liver cancer therapeutics market during the forecast period.
Development in Medical Technology
There have been several advancements in liver cancer therapeutics in recent years. Some of these advancements include targeted therapies. These therapies are drugs that are designed to specifically target cancer cells while sparing healthy cells. There are several targeted therapies approved for the treatment of liver cancer, including sorafenib, regorafenib, and lenvatini. Immunotherapy is a type of treatment that uses the body's own immune system to fight cancer. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have been approved for the treatment of liver cancer. Combination therapies involve using multiple drugs or treatment modalities to treat cancer. Several combination therapies have been approved for the treatment of liver cancer, including the combination of atezolizumab and bevacizumab. Surgical techniques for liver cancer have improved in recent years, including the use of laparoscopic and robotic surgeries. Laparoscopic and robotic surgeries have become increasingly popular in the treatment of liver cancer in India. These minimally invasive surgical techniques offer several benefits over traditional open surgeries, including smaller incisions, less pain and scarring, faster recovery times, and reduced risk of complications. In laparoscopic surgery, the surgeon makes several small incisions in the abdomen and inserts a laparoscope (a thin, flexible tube with a camera and light) and surgical instruments to remove the tumor. In robotic surgery, the surgeon uses a robotic system to control the surgical instruments and perform the surgery.
Personalized medicines involve tailoring treatment to an individual's specific genetic and molecular characteristics. Advances in genomic testing have allowed for the identification of specific genetic mutations in liver cancer, which can help guide treatment decisions. Such factors will accelerate the growth of the India liver cancer therapeutic market during the forecast period.
Increment in Healthcare Expenditure
As liver cancer is a serious health issue and requires specialized medical care, the cost of treatment can be significant. Therefore, an increase in healthcare expenditure can lead to increased access to medical care for patients with liver cancer, which can help to boost the demand for liver cancer therapeutics in India. Moreover, the Government of India has launched various healthcare initiatives and schemes, such as the Ayushman Bharat scheme, which aims to provide affordable and accessible healthcare to all citizens. Such initiatives and schemes can further boost the demand for liver cancer therapeutics in India, leading to market growth. National Cancer Grid is a network of cancer centers, research institutes, and universities that collaborate to provide standardized cancer care in India. The National Cancer Grid aims to improve the quality of cancer care, including liver cancer, by promoting research, training, and sharing best practices. Make in India aims to promote domestic manufacturing of medical devices and pharmaceuticals in India, including liver cancer therapeutics. By promoting local manufacturing, the initiative aims to reduce the cost of cancer treatment and improve access to affordable liver cancer therapeutics for patients. These initiatives aim to increase access to medical care, improve the quality of cancer care, reduce the cost of cancer treatment, and play a vital role in driving the growth of the India liver cancer therapeutics market.
Market Segmentation
The India liver cancer therapeutics market can be segmented by cancer type, therapy, route of administration, distribution channel, and region. By cancer type, the market can be segmented into hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, and liver metastasis. By therapy, the market can be segmented into targeted therapy, chemotherapy and radiation therapy, immunotherapy, and others. By route of administration, the market can be segmented into oral, intravenous, and others. By distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By region, the market can be segmented into North India, South India, East India, and West India.
Market Players
Natco Pharma Ltd., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Pvt. Ltd., Lupin Ltd., Biocon Ltd., and Hetero Labs Ltd. are some of the market players in the India liver cancer therapeutics market.
Report Scope:
In this report, the India liver cancer therapeutics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- India Liver Cancer Therapeutics Market, By Cancer Type:
- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Hepatoblastoma
- Angiosarcoma
- Liver Metastasis
- India Liver Cancer Therapeutics Market, By Therapy:
- Targeted Therapy
- Chemotherapy & Radiation Therapy
- Immunotherapy
- Others
- India Liver Cancer Therapeutics Market, By Route of Administration:
- Oral
- Intravenous
- Others
- India Liver Cancer Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- India Liver Cancer Therapeutics Market, By Region:
- North India
- South India
- East India
- West India
Company Profiles: Detailed analysis of the major companies present in the India liver cancer therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, and Liver Metastasis)
5.2.2. By Therapy (Targeted Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, and Others)
5.2.3. By Route of Administration (Oral, Intravenous, and Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
5.2.5. By Region (North India, South India, East India, and West India)
6. NORTH INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Cancer Type
6.2.2. By Therapy
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
7. SOUTH INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Cancer Type
7.2.2. By Therapy
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
8. EAST INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Cancer Type
8.2.2. By Therapy
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
9. WEST INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Cancer Type
9.2.2. By Therapy
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition
11.2. Product Development
11.3. Recent Developments
12. POLICY & REGULATORY LANDSCAPE
13. PORTERS FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. INDIA ECONOMIC PROFILE
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As Reported)
15.5. Recent Developments
15.5.1. Natco Pharma Ltd.
15.5.2. Dr. Reddy's Laboratories Ltd.
15.5.3. Intas Pharmaceuticals Ltd.
15.5.4. Mylan Pharmaceuticals Pvt. Ltd.
15.5.5. Lupin Ltd.
15.5.6. Biocon Ltd.
15.5.7. Hetero Labs Ltd.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, and Liver Metastasis)
5.2.2. By Therapy (Targeted Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, and Others)
5.2.3. By Route of Administration (Oral, Intravenous, and Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
5.2.5. By Region (North India, South India, East India, and West India)
6. NORTH INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Cancer Type
6.2.2. By Therapy
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
7. SOUTH INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Cancer Type
7.2.2. By Therapy
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
8. EAST INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Cancer Type
8.2.2. By Therapy
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
9. WEST INDIA LIVER CANCER THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Cancer Type
9.2.2. By Therapy
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition
11.2. Product Development
11.3. Recent Developments
12. POLICY & REGULATORY LANDSCAPE
13. PORTERS FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. INDIA ECONOMIC PROFILE
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As Reported)
15.5. Recent Developments
15.5.1. Natco Pharma Ltd.
15.5.2. Dr. Reddy's Laboratories Ltd.
15.5.3. Intas Pharmaceuticals Ltd.
15.5.4. Mylan Pharmaceuticals Pvt. Ltd.
15.5.5. Lupin Ltd.
15.5.6. Biocon Ltd.
15.5.7. Hetero Labs Ltd.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
